Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

S&P 500 Continues Holding Pattern Ahead of Inflation Data

Published 08/06/2021, 21:43
Updated 08/06/2021, 21:43
© Reuters.

© Reuters.

By Yasin Ebrahim

Investing.com – The S&P 500 ended flat Tuesday, as the humdrum action continued amid a lack of investor conviction to make bets on stocks ahead of inflation numbers that are expected to show the economy is running hot.  

The S&P 500 rose 0.02%, the Dow Jones Industrial Average was down 0.09%, or 30 points, and the Nasdaq Composite was up 0.31%.

Tech, which is on a three-week winning streak, ended flat as mixed performance in megacap tech despite falling U.S. bond yields  and weakness in semiconductors stocks weighed on the sector.

Google-parent Alphabet (NASDAQ:GOOGL), Amazon.com (NASDAQ:AMZN), Microsoft (NASDAQ:MSFT), and Facebook (NASDAQ:FB) ended mostly in the red.

The move lower in yields comes ahead of the Thursday's consumer inflation report, which many on Wall Street expect to reflect pent-up demand from consumers awash with cash.  

Not everyone agrees.

Morgan Stanley (NYSE:MS) noted that there is too much hype on inflation spiraling out of the control the recent strength in the CPI have not been broad-based, and the strong reflation in the sectors that had experienced pandemic blues could likely fade.

"Consumer balance sheet strength cannot be taken for granted – there are already signs that consumers are balking at the idea of buying cars or furniture as prices rise," Morgan Stanley said in a note.

Energy was among the biggest sector gainers on the day, led by Diamondback Energy (NASDAQ:FANG), Exxon Mobil (NYSE:XOM) and Nov (NYSE:NOV).

Aircraft maker Boeing (NYSE:BA), a major Dow component, was marginally higher after delivering 17 planes in May including 10 737 MAX jets.

Biogen (NASDAQ:BIIB), meanwhile, was unable to replicate its surge from a day earlier even as Wall Street analysts upgraded their outlook on the stock after the Food and Drug Administration approved the company’s Alzheimer’s drug on a conditional basis.

Biogen needs to complete a post marketing clinical trial to confirm the drug can improve cognition, the FDA said.

Oppenheimer upgraded its price target on the stock to $450 from $325 prior and maintained its outperform rating, citing expectations for an 80% probability of approval for the drug.

In the meme trade, Clover Health Investments (NASDAQ:CLOV) became the most mentioned stock on Reddit’s WallStreetBets forum on Tuesday, according to QuiverQuant, pushing its share price 85% higher.

AMC Entertainment (NYSE:AMC) was flat, while GameStop (NYSE:GME), BlackBerry (NYSE:BB), and Bed Bath & Beyond (NASDAQ:BBBY) traded mixed.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.